Joseph Lim is Professor of Medicine at Yale School of Medicine. OpenAlex indexes 394 publications with 22,509 citations (h-index 64); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Gastroenterology profiles in the FindMyKOL directory.
Data verified 3 Nov 2026
Overview
Updated 3 Nov 2026
Joseph Lim, MD, is Professor of Medicine at Yale School of Medicine. The public record shows 394 publications with 22,509 citations (h-index 64), centered on Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 5 companies, 1 NIH-funded awards (2006–2006).
- Most recent indexed publication: 2026 · Translational gastroenterology and hepatology
- Top research focus: Hepatitis C virus research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 3 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. 21 in PubMed. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 165.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Authored a comment on the tobevibart-elebsiran SOLSTICE phase 2 hepatitis D trial
listing Joseph.Lim@yale.edu
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tgh.amegroups.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 3 Nov 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
Sponsor: Romark Laboratories L.C.
- Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
Sponsor: Romark Laboratories L.C.
Industry payments
Updated 3 Nov 2026
5 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Davol Inc.Program year20246 payments
- Eli Lilly and CompanyProgram year20212 payments
- Gilead Sciences, Inc.Program year20211 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
77.3%Nucleoside and nucleotide reverse transcriptase inhibitors61.9%Vemlidy100%Part D<11 patientsHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor15.5%Entecavir100%Part D<11 patientsMetabolism & gastrointestinal
22.7%Bile Acid22.7%Ursodiol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 3 Nov 2026
1 NIH research award on record, funded 2006–2006 per NIH RePORTER. The latest:
Congress activity
Updated 3 Nov 2026
2 congress contributions (2016–2019) across AACR, ASCO per OpenAlex. The most recent:
- Abstract 4308: Multiplicative interaction between HIV infection status and FIB-4 in prediction of hepatocellular carcinoma risk
AACR (meeting unresolved)
AACR2016Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 3 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial.
Translational gastroenterology and hepatology
Comment2026 - AASLD ISDA Practice Guideline on treatment of chronic hepatitis B.
Hepatology (Baltimore, Md.)
Guideline2026 - Advanced Liver Fibrosis Predicts Liver Outcomes in Biopsy-proven Metabolic Dysfunction-associated Steatotic Liver Disease: A U.S.-based Single-center Retrospective Cohort Study.
Journal of clinical and translational hepatology
Article2024 - Outcomes of a 1-Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B.
Journal of viral hepatitis
Article2024
Most-cited works
by citation count (OpenAlex)- 01Longitudinal analyses reveal immunological misfiring in severe COVID-19Article2,060 citations2020
- 02
- 03ACG Clinical Guideline: Evaluation of Abnormal Liver ChemistriesArticle1,216 citations2016
- 04
- 05Diverse functional autoantibodies in patients with COVID-19Article992 citations2021
Network
Updated 3 Nov 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 3 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
cm.ynhh.org/physicians/joseph-lim
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cm.ynhh.org ↗ - Other
gastro.org/aga-leadership/council-and-sections/liver-biliary
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →gastro.org ↗ - Other
medicine.yale.edu/news-article/dr-joseph-k-lim-named-editor-in-chief-of-clinical-liver-disease
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗ - Other
medicine.yale.edu/profile/joseph-lim
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 3 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- Vice Chair
AGA Liver & Biliary council and section
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →gastro.org ↗ - Committee member
Viral Hepatitis (CLDF Committees)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →chronicliverdisease.org ↗ - Served on the Editorial Board of Gastroenterology
Hepatology (journal title truncated in source)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →media.mycme.com ↗ - Served in leadership roles for the ACG
AGA, and AASLD (specific posts not named)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →media.mycme.com ↗ - Director
Clinical Hepatology, Digestive Diseases
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Vice-Chief for Hepatology
Digestive Diseases
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Director
Yale Viral Hepatitis Program
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pmc.ncbi.nlm.nih.gov ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Media & interviews
press, podcasts and appearances- Podcast guest
Small Talk, Big Topics (episode on guideline development)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - CME webcast faculty
Clinical Tipping Points in Portal Hypertension
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →chronicliverdisease.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Harlan Krumholz, MD
Yale School of Medicine
Eric Winer, MD
Yale School of Medicine
Roy Herbst, MD, PhD
Yale School of Medicine
Robert Rosenheck, MD
Yale School of Medicine
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Kris Kowdley, MD
Washington State University
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai